María Sanchez-Ronco

7.2k total citations
15 papers, 1.1k citations indexed

About

María Sanchez-Ronco is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, María Sanchez-Ronco has authored 15 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Oncology. Recurrent topics in María Sanchez-Ronco's work include Lung Cancer Treatments and Mutations (9 papers), Cancer Genomics and Diagnostics (4 papers) and Lung Cancer Research Studies (4 papers). María Sanchez-Ronco is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Cancer Genomics and Diagnostics (4 papers) and Lung Cancer Research Studies (4 papers). María Sanchez-Ronco collaborates with scholars based in Spain, United States and France. María Sanchez-Ronco's co-authors include José Javier Sánchez, Rafael Rosell, Miquel Tarón, Bartomeu Massutí, José Miguel Sánchez, Enriqueta Felip, Cristina Queralt, Teresa Morán, Carlos Camps and Vicente Alberola and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

María Sanchez-Ronco

15 papers receiving 1.1k citations

Peers

María Sanchez-Ronco
Navonil De Sarkar United States
Maria Trypaki Greece
Kiyoko Kuwata Japan
V. A. Miller United States
Thomas Goddemeier Germany
S. Gail Eckhardt United States
F. Cardenal Spain
Jaromı́r Roubec Czechia
Ira A. Oliff United States
Jerry Haney United States
Navonil De Sarkar United States
María Sanchez-Ronco
Citations per year, relative to María Sanchez-Ronco María Sanchez-Ronco (= 1×) peers Navonil De Sarkar

Countries citing papers authored by María Sanchez-Ronco

Since Specialization
Citations

This map shows the geographic impact of María Sanchez-Ronco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by María Sanchez-Ronco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites María Sanchez-Ronco more than expected).

Fields of papers citing papers by María Sanchez-Ronco

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by María Sanchez-Ronco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by María Sanchez-Ronco. The network helps show where María Sanchez-Ronco may publish in the future.

Co-authorship network of co-authors of María Sanchez-Ronco

This figure shows the co-authorship network connecting the top 25 collaborators of María Sanchez-Ronco. A scholar is included among the top collaborators of María Sanchez-Ronco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with María Sanchez-Ronco. María Sanchez-Ronco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
3.
Campelo, Rosario García, Enriqueta Felip, Bartomeu Massutí, et al.. (2013). Phase IB study of olaparib (AZD2281) plus gefitinib in EGFR-mutant patients (p) with advanced non-small-cell lung cancer (NSCLC) (NCT01513174/GECP-GOAL).. Journal of Clinical Oncology. 31(15_suppl). 2581–2581. 5 indexed citations
4.
Wei, Jia, Teresa Morán, Zhengyun Zou, et al.. (2013). Customized chemotherapy in metastatic non-small cell lung cancer (NSCLC).. PubMed. 2(3). 180–8. 3 indexed citations
5.
6.
Santarpía, Mariacarmela, María Sanchez-Ronco, Carlota Costa, et al.. (2011). mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients. Journal of Translational Medicine. 9(1). 163–163. 22 indexed citations
7.
Molina‐Vila, Miguel Ángel, María Sanchez-Ronco, Teresa Morán, et al.. (2010). First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Lung Cancer. 72(1). 84–91. 31 indexed citations
8.
Carcereny, Enric, José Luis Ramírez, María Sanchez-Ronco, et al.. (2009). Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients. Lung Cancer. 68(3). 491–497. 9 indexed citations
9.
Santarpía, Mariacarmela, Giuseppe Altavilla, Mireia Margelí Vila, et al.. (2008). PIK3CA Mutations and BRCA1 Expression in Breast Cancer: Potential Biomarkers for Chemoresistance. Cancer Investigation. 26(10). 1044–1051. 11 indexed citations
10.
Boukovinas, Ioannis, Chara Papadaki, Pedro Méndez, et al.. (2008). Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients. PLoS ONE. 3(11). e3695–e3695. 103 indexed citations
11.
Garrido, Pilar, J.L. González-Larriba, Amelia Insa, et al.. (2007). Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non–Small-Cell Lung Cancer Patients: The Spanish Lung Cancer Group Trial 9901. Journal of Clinical Oncology. 25(30). 4736–4742. 80 indexed citations
12.
Cobo, Manuel, Dolores Isla, Bartomeu Massutí, et al.. (2007). Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 25(19). 2747–2754. 344 indexed citations
13.
Tarón, Miguel, Yukito Ichinose, Rafael Rosell, et al.. (2005). Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas. Clinical Cancer Research. 11(16). 5878–5885. 280 indexed citations
14.
Ramírez, José Luis, Rafael Rosell, Miquel Tarón, et al.. (2005). 14-3-3σ Methylation in Pretreatment Serum Circulating DNA of Cisplatin-Plus-Gemcitabine-Treated Advanced Non–Small-Cell Lung Cancer Patients Predicts Survival: The Spanish Lung Cancer Group. Journal of Clinical Oncology. 23(36). 9105–9112. 94 indexed citations
15.
Rosell, Rafael, Enriqueta Felip, Miquel Tarón, et al.. (2004). Gene Expression as a Predictive Marker of Outcome in Stage IIB-IIIA-IIIB Non-Small Cell Lung Cancer After Induction Gemcitabine-Based Chemotherapy Followed By Resectional Surgery. Clinical Cancer Research. 10(12). 4215s–4219s. 112 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Navonil De Sarkar Breakdown of academic impact, for papers by Maria Trypaki Breakdown of academic impact, for papers by Kiyoko Kuwata Breakdown of academic impact, for papers by V. A. Miller Breakdown of academic impact, for papers by Thomas Goddemeier Breakdown of academic impact, for papers by S. Gail Eckhardt Breakdown of academic impact, for papers by F. Cardenal Breakdown of academic impact, for papers by Jaromı́r Roubec Breakdown of academic impact, for papers by Ira A. Oliff Breakdown of academic impact, for papers by Jerry Haney
Rankless by CCL
2026